Bellerophon Therapeutics, Inc. is a U.S.-based clinical-stage pharmaceutical company primarily focused on developing novel therapies for various cardiopulmonary conditions. Its flagship product is INOpulse, a proprietary platform designed to deliver pulsatile nitric oxide, specifically targeting pulmonary hypertension (PH). The company is actively advancing the development of INOpulse across multiple indications: Currently, INOpulse is undergoing a Phase 3 clinical trial for pulmonary hypertension linked to fibrotic interstitial lung disease.